NEXLETOL Drug Patent Profile

Which patents cover Nexletol, and what generic alternatives are available?

Nexletol is a drug marketed by Esperion Theraps Inc and is included in one NDA. There are seven patents protecting this drug and one Paragraph IV challenge.

This drug has eighty-one patent family members in twenty-four countries.

The generic ingredient in NEXLETOL is bempedoic acid. One supplier is listed for this compound. Additional details are available on the bempedoic acid profile page.

DrugPatentWatch^® Generic Entry Outlook for Nexletol

Nexletol was eligible for patent challenges on February 21, 2024.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be December 3, 2030. This may change due to patent challenges or generic licensing.

There have been five patent litigation cases involving the patents protecting this drug, indicating strong interest in generic launch. Recent data indicate that 63% of patent challenges are decided in favor of the generic patent challenger and that 54% of successful patent challengers promptly launch generic drugs.

There is one tentative approval for the generic drug (bempedoic acid), which indicates the potential for near-term generic launch.

Indicators of Generic Entry

Summary for NEXLETOL

International Patents:	81
US Patents:	7
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for NEXLETOL

Paragraph IV (Patent) Challenges for NEXLETOL

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
NEXLETOL	Tablets	bempedoic acid	180 mg	211616	9	2024-02-21

US Patents and Regulatory Information for NEXLETOL

NEXLETOL is protected by seven US patents and two FDA Regulatory Exclusivities.

This potential generic entry date is based on patent 7,335,799.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes	11,744,816
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes	11,613,511			Y
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes	11,760,714		Y
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes	11,926,584
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes	12,404,227			Y
Esperion Theraps Inc	NEXLETOL	bempedoic acid	TABLET;ORAL	211616-001	Feb 21, 2020		RX	Yes	Yes	12,398,087		Y	Y

International Patents for NEXLETOL

See the table below for patents covering NEXLETOL around the world.

Country	Patent Number	Title	Estimated Expiration
Brazil	112021025928
Mexico	2021015936	METODOS PARA PREPARAR ACIDO BEMPEDOICO Y COMPOSICIONES DEL MISMO. (METHODS OF MAKING BEMPEDOIC ACID AND COMPOSITIONS OF THE SAME.)
Russian Federation	2766085	ФИКСИРОВАННЫЕ КОМБИНАЦИИ И СОСТАВЫ, СОДЕРЖАЩИЕ ЕТС1002 И ЭЗЕТИМИБ, И СПОСОБЫ ЛЕЧЕНИЯ ИЛИ УМЕНЬШЕНИЯ РИСКА РАЗВИТИЯ СЕРДЕЧНО-СОСУДИСТОГО ЗАБОЛЕВАНИЯ (FIXED COMBINATIONS AND COMPOUNDS CONTAINING ETC-1002 AND EZETIMIBE, AND METHOD FOR TREATING OR REDUCING THE RISK OF DEVELOPING A CARDIOVASCULAR DISEASE)
Brazil	PI0318046	compostos de hidroxila, seu usos, e composições farmacêuticas
European Patent Office	2404890	Composés hydroxyle et compositions pour la gestion du cholestérol et utilisations associées (Hydroxyl compounds and compositions for cholesterol management and related uses)
Cyprus	1119404
World Intellectual Property Organization (WIPO)	2020257573

Supplementary Protection Certificates for NEXLETOL

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2404890	132020000000112	Italy		PRODUCT NAME: ACIDO BEMPEDOICO, O UN SUO SALE FARMACEUTICAMENTE ACCETTABILE, IDRATO, SOLVATO, O LORO MISCELA(NUSTENDI); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/20/1424, 20200331
2404890	C202030044	Spain		PRODUCT NAME: ACIDO BEMPEDOICO, O UNA SAL FARMACEUTICAMENTE ACEPTABLE, HIDRATO, SOLVATO O MEZCLA DE LOS MISMOS; NATIONAL AUTHORISATION NUMBER: EU/1/20/1424; DATE OF AUTHORISATION: 20200327; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1424; DATE OF FIRST AUTHORISATION IN EEA: 20200327
2404890	2090035-3	Sweden		PRODUCT NAME: BEMPEDOIC ACID, OR A PHARMACEUTICALLY ACCEPTABLE SALT,HYDRATE,SOLVATE OR MIXTURE THEREOF; REG. NO/DATE: EU/1/20/1424 20200331
2404890	C 2020 031	Romania		PRODUCT NAME: ACID BEMPEDOIC, SAU O SARE, HIDRAT, SOLVAT ACCEPTABILE FARMACEUTIC SAU AMESTECUL ACESTORA; NATIONAL AUTHORISATION NUMBER: EU/1/20/1424; DATE OF NATIONAL AUTHORISATION: 20200327; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/20/1424; DATE OF FIRST AUTHORISATION IN EEA: 20200327
2404890	LUC00174	Luxembourg		PRODUCT NAME: BEMPEDOIC ACID, OR A PHARMACEUTICALLY ACCEPTABLE SALT, HYDRATE, SOLVATE, OR MIXTURE THEREOF; AUTHORISATION NUMBER AND DATE: EU/1/20/1424 20200331
2404890	C02404890/01	Switzerland		PRODUCT NAME: BEMPEDOINSAEURE; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 67583 14.12.2020
2404890	2020C/534	Belgium		PRODUCT NAME: ACIDE BEMPEDOIQUE OU UN SEL, HYDRATE, PRODUIT DE SOLVATATION OU MELANGE DE CEUX-CI, PHARMACEUTIQUEMENT ACCEPTABLES; AUTHORISATION NUMBER AND DATE: EU/1/20/1424 20200331

Investment Scenario, Market Dynamics, and Financial Trajectory for NEXLETOL

Last updated: February 3, 2026

Executive Summary

NEXLETOL (bempedoic acid) is a novel lipid-lowering agent developed by Esperion Therapeutics, approved by the U.S. Food and Drug Administration (FDA) in 2020 for patients with heterozygous familial hypercholesterolemia (HeFH) or established atherosclerotic cardiovascular disease (ASCVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C). This analysis evaluates the investment prospects, market environment, and financial outlook for NEXLETOL, considering competitive positioning, market potential, regulatory landscape, and evolving cardiovascular treatment paradigms.

Market Overview and Dynamics

Global and U.S. Market Size

Metric	2022	2027 (Projected)	CAGR (2022-2027)
Global Hyperlipidemia Market	$25 billion	$35 billion	7%
U.S. Dyslipidemia Market	$8 billion	$12 billion	8.2%

Source: GlobalData (2022), IQVIA (2023)

The global hyperlipidemia market is driven by increasing prevalence of cardiovascular disease, aging populations, and rising awareness of lipid management. NEXLETOL's market share hinges on its competitive positioning against established therapies such as statins, PCSK9 inhibitors, and newer agents.

Key Drivers

• Unmet Medical Need: Approximately 15-20% of high-risk patients cannot reach LDL-C targets with statins alone, creating demand for adjunctive therapies.
• Guideline Endorsements: Recent guidelines, including the 2018 ACC/AHA, recommend additional LDL-C lowering agents for high-risk populations, broadening potential use.
• Insurance Coverage & Reimbursement: Favorable payer coverage bolsters access; NEXLETOL's pricing (~$10,600/year in the U.S., per 2022 data) influences adoption.

Market Penetration Factors

Aspect	Impact
Physician Adoption	Influenced by efficacy, safety profile, and ease of combination with statins.
Patient Preference	Preference for oral agents over injectable therapies like PCSK9 inhibitors enhances uptake.
Competitive Landscape	Dominated by statins and PCSK9 inhibitors; NEXLETOL faces competition from ezetimibe and emerging therapies.

Competitive Landscape

Key Competitors

Drug	Class	Indication	Market Share (2022)	Pricing	Administration
Atorvastatin, Rosuvastatin	Statins	First-line LDL-C reduction	60%	$10-$15/month	Oral
Ezetimibe (Zetia)	Cholesterol absorption inhibitor	Adjunct to statins	15%	$7-$20/month	Oral
Inclisiran (Leqvio)	siRNA-based PCSK9 inhibitor	Secondary prevention	Emerging	$20,000/year	Injection
Alirocumab, Evolocumab	Monoclonal antibodies	Severe cases	~10% combined	~$14,000/year	Injection

NEXLETOL’s Positioning

• Advantages: Oral administration, small molecule, potential for combination with statins, favorable safety profile.
• Limitations: Less potent LDL-C lowering compared to PCSK9 inhibitors, somewhat niche indication focus.

Financial Trajectory and Investment Outlook

Sales and Revenue Projections

Year	Estimated U.S. Sales	Global Sales	Notes
2022	~$100 million	N/A	Post-approval launch, initial uptake
2023	~$200 million	~$300 million	Early adoption, expanded prescriber base
2024	~$500 million	~$750 million	Wider awareness, guideline inclusion
2025	~$1 billion	~$1.5 billion	Peak market penetration expected
2026+	Stabilization, plateauing	Similar to 2025	Competition and market saturation considerations

Sources: Company filings, analyst estimates (e.g., EvaluatePharma, 2022)

Revenue Drivers

• Market Penetration Rate: Estimated at 10-15% of eligible high-risk patients by 2025.
• Pricing Strategy: Cost-effective relative to PCSK9 inhibitors; insurer negotiations influence net prices.
• Combination Therapy Expansion: Growth potential in combination with statins.

Cost Structure and Profitability

• R&D Expenses: Estimated ~$200 million annually for ongoing research, post-market surveillance, and pipeline development.
• Manufacturing Costs: Low relative to injectable counterparts due to oral formulation.
• Margin Outlook: Expected gross margin of 70-80%; net margins variable based on commercialization efficiency.

Regulatory Landscape and Policy Impact

Key Policies

• FDA Labeling: Expanded indications and label updates influence prescribing patterns.
• Pricing & Reimbursement: CMS and private payers’ policies affect access; value-based pricing considerations are emerging.

Potential Regulatory Challenges

• Long-term safety data viability
• Off-label use limitations
• Competitive approval of biosimilars or novel agents

Comparison with Peers

Aspect	NEXLETOL	PCSK9 inhibitors	Ezetimibe
Administration	Oral	Injectable	Oral
Efficacy (LDL-C Reduction)	~20-25%	50-60%	~20-25%
Pricing (Approximate)	$10,600/year	$14,000/year	$240/year (generic ezetimibe)
Taken with Statins	Yes	Yes	Yes

Market Entry and Expansion Strategies

• Physician Education: Focus on high-intensity statin-intolerant populations.
• Payer Negotiations: Demonstrate cost-effectiveness for broader coverage.
• Pipeline Development: Explore additional indications (e.g., heterozygous hypercholesterolemia in pediatric populations).

Deep Dive: Investment Risks and Opportunities

Risks

• Market Uptake Uncertainty: Slow adoption due to established therapies.
• Pricing Pressure: Price reductions in competitive drugs may squeeze margins.
• Regulatory Delays: Long-term safety concerns could limit indications.
• Patent Expiry and Biosimilars: Potential for generic competition.

Opportunities

• Expanding Indications: Potential to widen use in other hyperlipidemia subpopulations.
• Combination Therapies: Co-formulations or synergistic regimens.
• Global Expansion: Emerging markets with rising cardiovascular disease burdens.
• Pipeline Innovations: Development of next-generation lipid-lowering agents.

Conclusion

NEXLETOL represents a niche segment within the broader hyperlipidemia market, with growth potential driven by unmet needs and favorable administration profile. Its financial trajectory depends on successful clinician adoption, favorable reimbursement, and competitive dynamics. While it faces stiff competition from potent injectable therapies, its oral formulation and targeted niche may secure steady growth, particularly if expanding indications and pipeline innovations materialize.

---

Key Takeaways

• NEXLETOL is positioned as an adjunct therapy for high-risk cardiovascular patients not at LDL-C targets.
• Market penetration is projected to reach approximately 15-20% of eligible patients by 2025.
• The drug’s pricing (~$10,600/year) and oral administration give it a competitive edge over injectables.
• Growth prospects hinge on adoption rates, payer coverage, and pipeline extension.
• Regulatory and competitive hurdles include safety data updates and emerging therapies.

---

FAQs

1. What are the main factors influencing NEXLETOL’s market success?
Physician adoption, payer reimbursement policies, competitive efficacy and safety profiles, and expansion into new indications primarily determine its market success.

2. How does NEXLETOL compare with PCSK9 inhibitors in efficacy and cost?
NEXLETOL offers approximately 20-25% LDL-C reduction at roughly $10,600 annually, whereas PCSK9 inhibitors provide 50-60% reduction at about $14,000 annually, but with injectable administration.

3. What are the primary regulatory challenges for NEXLETOL?
Ensuring long-term safety data, maintaining label expansions, and navigating potential off-label restrictions pose regulatory challenges.

4. How might healthcare policies affect NEXLETOL’s growth?
Value-based payment models and pricing negotiations could influence coverage, access, and profitability, especially amidst evolving cardiovascular treatment guidelines.

5. What is the projected long-term financial trajectory for NEXLETOL?
Sales are expected to approach $1 billion globally by 2025, with growth tapering as market saturation occurs, contingent on competitive dynamics and pipeline developments.

---

Sources:

1. GlobalData (2022). Hyperlipidemia Market Analysis.
2. IQVIA (2023). US Prescription Data.
3. Esperion Therapeutics. FDA Approval Announcement (2020).
4. EvaluatePharma (2022). Oncology and Cardiovascular Market Reports.
5. CDC, American Heart Association (2022). Cardiovascular Disease Statistics.